Tackling unmet MS-related cognitive challenges

Controlled studies comparing therapies with respect to their effects on rate of cognitive decline in multiple sclerosis (MS) are lacking. In addition, current open-label studies or clinical trials on cognitive functioning have not selected patients on criteria for cognitive dysfunction. So, the question remains if a cognitive-based early initiation of highly effective treatment should be considered. Researchers from Spain initiated the CogEval project, comparing high efficacy versus usual first-line treatment in patients with cognitive dysfunction, evaluated via Processing Speed Test (PST) [1]. The PST is a self-administered iPad®-based tool to measure MS-related deficits in processing speed and its use has shown an advantage over pen-and-paper cognitive batteries because of its ease of administration and a standardised scoring system. The aim of CogEval is to determine whether early initiation of highly effective disease-modifying therapy (DMT) in ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 16 December, 202016 December, 2020